Mumbai (Maharashtra) [India], Mumbai-headquartered pharma major Cipla's US subsidiary has received final approval from the United States Food and Drug Administration (USFDA) for its Lanreotide Injection 120 mg/0.5 mL, 90 mg/0.3 mL and 60 Have done. mg/0. ML Injection, pre-filled and ready-to-use, is an AP-rated therapeutic generic version of Somatulin Depot Injection that is used in the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumors (GEPNETs), the company said in its stock filing. This information has been given. Explaining the significance of the approval in the US, “The approval for the generic version of lanreotide acetate is in line with Cipla's growth strategy in the complex products segment and will strengthen Cipla's position in the US market. Following the information, Cipla's share price rose more than 2.07 per cent from Tuesday's closing price of Rs 1,442.3, indicating a change of 2.02 per cent at the time of filing, which remains valid as long as the product complies with USFDA regulations and standards. .It reports US sales of somatulin depot (Lanreotide) were approximately $898M for the 12-month period ending March 2024, according to IQVIA (IMS Health) Last week, the Indian pharmaceutical giant reported its fourth quarter earnings In which consolidated net profit was reported at Rs 939 crore, which is 7 percent more than last year's Rs 525.6 crore. The company beat Street estimates of Rs 923.5 crore as Cipla's operating profit or EBITDA rose 12 per cent year-on-year to Rs 1,316 crore, while margins expanded by 80 basis points. Established in 1935, Cipla is a global pharmaceutical company known for its strength in the respiratory sector. , Anti-Retroviral, Urology, Cardiology Anti-Infectious, and CNS sections. Its 47 manufacturing sites around the world produce more than 50 dosage forms and more than 1,500 products to meet the needs of more than 80 markets.Cipla is ranked third largest in pharma in India.